More about

University Medical Center Groningen

News
February 16, 2022
3 min read
Save

Axi-cel CAR-T significantly improves EFS among older patients with non-Hodgkin lymphoma

Second-line therapy with axicabtagene ciloleucel conferred a greater than eightfold increase in median EFS compared with standard-of-care treatment for older patients with diffuse large B-cell lymphoma, according to phase 3 study results.